The CDC released updated estimates of antimicrobial resistance’s real-world impact in the US, reporting 9.7 million infections and 50,800 deaths annually from urgent, serious, and concerning AMR threats. The report enumerated 19 bacterial and fungal pathogens driving the burden, including cases occurring outside hospital settings. CDC emphasized the risk that resistance has outpaced existing antimicrobial options and highlighted the need for new drug development. The update also renewed calls for policy solutions designed to fix the economics of antibiotic innovation. For biotech stakeholders, the key takeaway is that AMR remains quantifiable and policy-visible at national scale—supporting continued demand for novel mechanisms, better diagnostics, and targeted stewardship strategies tied to high-burden pathogens.